Euglobulin-based method for determining the biological activity of defibrotide

    公开(公告)号:US11236328B2

    公开(公告)日:2022-02-01

    申请号:US17459169

    申请日:2021-08-27

    Applicant: GENTIUM S.R.L.

    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.

    EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE

    公开(公告)号:US20210388350A1

    公开(公告)日:2021-12-16

    申请号:US17459169

    申请日:2021-08-27

    Applicant: GENTIUM S.R.L.

    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.

    Cellular-based method for determining the biological activity of defibrotide

    公开(公告)号:US10393731B2

    公开(公告)日:2019-08-27

    申请号:US15529814

    申请日:2015-11-23

    Applicant: GENTIUM S.R.L.

    Abstract: The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.

    CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDE

    公开(公告)号:US20230194502A1

    公开(公告)日:2023-06-22

    申请号:US18170644

    申请日:2023-02-17

    Applicant: GENTIUM S.R.L.

    CPC classification number: G01N33/5014 G01N33/5064

    Abstract: The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.

    CELLULAR-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE

    公开(公告)号:US20200057051A1

    公开(公告)日:2020-02-20

    申请号:US16551505

    申请日:2019-08-26

    Applicant: GENTIUM S.R.L.

    Abstract: The present invention relates to cell-based methods for determining the biological activity of defibrotide. In particular, the invention provides a method for assessing the potency of defibrotide by assessing the viability of mammalian cells in the presence of at least one cytotoxic agent and one or more concentrations of defibrotide. Such methods are particularly useful for standardizing pharmaceutical compositions comprising defibrotide.

Patent Agency Ranking